Antiemetic effectiveness of ondansetron and granisetron in patients with breast cancer treated with cyclophosphamide

American Journal of Health-System Pharmacy

Volumn 61, Issue 8, 2004, Pages 781-786

  Dempsey, Cindy L ^a,b   Coop, Andrew J ^c   Shillington, Alicia ^a,b   Farley, P Anne ^a,b   Eberhardt, Douglas R ^d   O'Briant, Sharon ^e  

^a EPI Q Inc   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c HOFFMANN LA ROCHE INC   (United States)

^d Clin Investigations Med Affairs

^e Roche Laboratories Inc   (United States)

Author keywords

Antiemetics; Antineoplastic agents; Breast neoplasms; Cyclophosphamide; Dexamethasone; Dosage; Granisetron; Nausea; Ondansetron; Radiation; Toxicity; Vomiting

Indexed keywords

CYCLOPHOSPHAMIDE; GRANISETRON; ONDANSETRON;

ADULT; ANTIEMETIC ACTIVITY; ARTICLE; BREAST CANCER; CHEMOTHERAPY INDUCED EMESIS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 8344286352     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/61.8.781     Document Type: Article

References (24)

1. Rodabaugh KJ, Bloss JD. Breast cancer prevention. Clin Obstet Gynecol. 2001; 44:478-84.
2. Dombernowsky P, Gehl J, Boesgaard M et al. Treatment of metastatic breast cancer with paclitaxel and doxorubicin. Semin Oncol. 1995; 22:13-7.
3. Hesketh PJ, Harvey WH, Harker WG et al. A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis. J Clin Oncol. 1994; 12:596-600.
4. Kleisbauer JP, Garcia Giron C, Antimi M et al. Granisetron plus methylprednisolone for the control of high-dose cisplatin-induced emesis. Anticancer Drugs. 1998; 9:387-92.
5. Li-Qing L, Zhon-Sheng T, Peng C. Phase III clinical trial of ondansetron. Chin J Clin Oncol. 1998; 25:372-3.
6. Chua DT, Sham JS, Kwong DL et al. Comparative efficacy of three 5-HT3 antagonists (granisetron, ondansetron, and tropisetron) plus dexamethasone for the prevention of cisplatin-induced acute emesis: a randomized crossover study. Am J Clin Oncol. 2000; 23:185-91.
7. Garcia-del-Muro X, Vadell C, Perez Manga G et al. Randomized double-blind study comparing tropisetron alone and in combination with dexamethasone in the prevention of acute and delayed cisplatin-induced emesis. Eur J Cancer. 1998; 34:193-5.
8. American Society of Health-System Pharmacists. ASHP therapeutic guidelines on the pharmacologic management of nausea and vomiting in adult and pediatrie patients receiving chemotherapy or radiation therapy or undergoing surgery. Am J Health-Syst Pharm. 1999; 56:729-64.
9. Gralla RJ. Management of nausea and vomiting. In: Pazdur R, Coia LR, Hoskins WJ et al., eds. Cancer management: a multidisciplinary approach. 7th ed. New York: The Oncology Group; 2003:839-49.
10. Matsumoto S, Kawasaki Y, Mikami M et al. Relationship between cancer chemotherapeutic drug-induced delayed emesis and plasma levels of substance P in two patients with small cell lung cancer. Jpn J Cancer Chemother. 1999; 26:535-8.
11. Dover KR. Prevention of chemotherapy-induced nausea and vomiting. Top Drug Ther. 1996; 38(6):1-12.
12. Gralla RJ, Osoba D, Kris MG et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol. 1999; 17:2971-94.
13. Beck TM. The pattern of emesis following high-dose cyclophosphamide and the anti-emetic efficacy of ondansetron. Anticancer Drugs. 1995; 6:237-42.
14. Hesketh PJ, Kris MG, Grunberg SM et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol. 1997; 15:103-9.
15. Ruff P, Paska W, Goedhals L et al. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. Oncology. 1994; 51:113-8.
16. Seynaeve C, Schuller J, Buser K et al. Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis: a multicentre, double-blind, randomised, parallel group study. Br J Cancer. 1992; 66:192-7.
17. Beck TM, Hesketh SM, Madajewicz S et al. Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting. J Clin Oncol. 1992; 10:1969-75.
18. Lane M, Grunberg S, Lester EP et al. A double-blind comparison of three dose levels of IV ondansetron (OND) in the prevention of cisplatin (DDP)-induced nausea and vomiting. Proc Am Soc Clin Oncol. 1990; 9:329.
19. Italian Group for Antiemetic Research. Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Lancet. 1992; 340:96-9.
20. Pectasides D, Mylonakis A, Varthalitis J et al. Comparison of two different doses of ondansetron plus dexamethasone in the prophylaxis of cisplatin-induced emesis. Oncology. 1997; 54:1-6.
21. Tsavaris N, Kosmas CH, Vadiaka M et al. Efficacy of ondansetron treatment for acute emesis with different dosing schedules 8 vs 32 mg: a randomized study. J Exp Clin Cancer Res. 2001; 20:29-34.
22. Sweetland L, Fowler PA, Thomas M. Duration of the inhibitory effect of intravenous ondansetron on intradermal 5-HT-induced flare. Br J Clin Pharmacol. 1991; 565P. Abstract.
23. Roila F, Del Favero A. Ondansetron clinical pharmacokinetics. Clin Pharmacokinet. 1995; 29:95-109.
24. Navari RM, Reinhardt RR, Gralla RJ et al. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. N Engl J Med. 1999; 340:190-5.